Who Paid My Doc
Yescarta
Drug Cellt
NDC 71287-119-02
General payments
$7,873,998
Research payments
$62,700,010
Through program year 2025, $7,873,998 in general payments and $62,700,010 in research payments were reported against Yescarta (Cellt).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $2,063,318 | 5,298 |
| 2025 | Research | $7,763,962 | 640 |
| 2024 | General | $1,239,455 | 2,637 |
| 2024 | Research | $12,177,694 | 1,027 |
| 2023 | General | $1,274,437 | 2,972 |
| 2023 | Research | $8,100,920 | 658 |
| 2022 | General | $1,668,890 | 1,746 |
| 2022 | Research | $9,105,439 | 625 |
| 2021 | General | $735,309 | 597 |
| 2021 | Research | $11,679,562 | 966 |
| 2020 | General | $873,613 | 1,483 |
| 2020 | Research | $13,872,434 | 989 |
| 2019 | General | $18,977 | 8 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 84 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 49 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
14,741 general · 4,905 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.